Search Results
Your search for The A,The A matches 32343 pages
Showing 25051 - 25100Help Your Patients Understand the Latest Research to Be Highlighted at the 2013 ASCO Annual Meeting
Starting on May 15, direct your patients to Cancer.Net, ASCO’s patient information website, to find easy-to-read summaries of studies released in advance of this year’s Annual Meeting. In addition, encourage them to listen to a panel discussion and Q&A session about these latest advances in a...
From One to Many, Here and Around the World
The Conquer Cancer Foundation Grants and Awards Program has grown tremendously in 30 years, from supporting just one researcher in the United States to thousands working around the world. These investigators are performing breakthrough research in all aspects of cancer and making discoveries that...
ASCO's Pre-Annual Meeting Seminar Series to Offer a New, Fourth Focus: Genetics and Genomics
ASCO’s pre–Annual Meeting seminar series continues this year, offering intimate, discussion-based seminars just before the start of the Annual Meeting in late May. The seminars are an excellent educational opportunity for health providers who are attending the Annual Meeting but would like to drill ...
New ASCO/AAHPM Project Will Harness Technology to Foster Improved Palliative Care in Oncology
ASCO and the American Academy of Hospice and Palliative Care Medicine (AAHPM) recently announced a joint initiative to support delivery of high-quality palliative care in medical oncology. The initiative is funded by ASCO’s first-ever grant from the Agency for Health Care Research Quality. The...
AACR Elects Carlos L. Arteaga, MD, as President-elect 2013-2014
The members of the American Association for Cancer Research (AACR) have elected Carlos L. Arteaga, MD, as their President-elect for 2013-2014. Dr. Arteaga is Professor of Medicine and Cancer Biology at Vanderbilt University School of Medicine where he holds the Donna S. Hall Chair in Breast Cancer...
SIDEBAR: Three Breakthrough Therapy Designations for Ibrutinib from the FDA
In February 2013, FDA granted Breakthrough Therapy Designations for ibrutinib as a monotherapy for the treatment of patients with relapsed or refractory mantle cell lymphoma and as a monotherapy for the treatment of patients with Waldenström’s macroglobulinemia, both of which are also B-cell...
A Promising New Agent's Road to Approval in CLL Raises Questions, Stirs Controversy
Early trial results in single-agent therapy with the oral Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib have produced excellent responses in patients with chronic lymphocytic leukemia (CLL). Moreover, ibrutinib is extremely well tolerated, allowing patients to remain on trial and receive the...
Access to Care: Who Gets Referred to a Medical Oncologist and/or Another Cancer Specialist and Who Receives Treatment for Advanced Cancer?
What factors determine who is referred to a medical oncologist and receives treatment for advanced cancers? Several articles in the Journal of Oncology Practice suggest that factors influencing referral and treatment go beyond the patient’s medical condition and preference and include such details...
SIDEBAR: Take-home Message
Perhaps the most important take-home point of our study is that physicians should consider counseling colorectal cancer survivors to adopt a more physically active lifestyle that is consistent with a patient’s abilities and overall medical condition. Physicians should be reminded that most patients ...
More Recreational Physical Activity Associated with Reduced All-cause Mortality in Patients with Colorectal Cancer
In a study recently reported in Journal of Clinical Oncology, Peter T. Campbell, PhD, and colleagues from the Epidemiology Research Program of the American Cancer Society, Atlanta, found that more recreational physical activity before and after a diagnosis of colorectal cancer was associated with...
SIDEBAR: Prolonged VEGF Inhibition
The so-called TML (Treatment across Multiple Lines) study reported by Bennouna and colleagues investigated the efficacy of bevacizumab (Avastin) beyond progression from first- to second-line therapy in advanced colorectal cancer, a strategy that was supported by data from observational cohort...
Benefit of Continued Antiangiogenic Treatment with Bevacizumab after Progression in Metastatic Colorectal Cancer
As reported recently in Lancet Oncology by Jaafar Bennouna, MD, of Institut de Cancérologie de l’Ouest, Nantes, France, and colleagues, the phase III ML18147 trial showed a survival benefit with continued bevacizumab (Avastin) treatment after first progression in metastatic colorectal cancer.1 The...
Sentinel Node Biopsy in Melanoma: Essential or Optional?
Is sentinel node biopsy in melanoma an essential component of care? Despite a large multinational trial and recently published or updated guidelines, the question is still a thorny one according to experts who debated the issue at the recent meeting of the Society of Surgical Oncology in...
Medical Oncologists Underestimate Resectability of Liver Metastases
Medical oncologists are apt to underestimate the resectability of liver metastases in patients with colorectal cancer and therefore often fail to refer potential surgical candidates for surgical consultation, according to a study presented at the 18th Annual Conference of the National Comprehensive ...
CancerLinQ Prototype Demonstrates Use of Big Data in Clinical Care
ASCO has unveiled the prototype of a computer system that will allow oncologists, from their desks, to leverage “big data” to measure the quality of care that their practices provide. The prototype is a major step in the development of CancerLinQ, a system that will eventually allow millions of...
SIDEBAR: The Ethical Imperative of Clinical Equipoise
In her editorial about the RESONATE trial (page 1), Dr. O’Brien raises the issue of equipoise in this phase III clinical trial that compares the efficacy of ibrutinib and ofatumumab (Arzerra) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who are not appropriate...
Ibrutinib CLL Trial: Where Is the Equipoise?
The RESONATE trial is randomly assigning patients with refractory or relapsed CLL to either ofatumumab (Arzerra) or the investigational oral agent ibrutinib. Ofatumumab is an anti-CD20 monoclonal antibody like rituximab (Rituxan), but is more potent as a single agent. It was approved for refractory ...
Does Every Melanoma Patient with a Positive Sentinel Node Need More Lymph Nodes Removed?
When sentinel node biopsy was shown to predict whether early melanoma had spread to regional lymph nodes, it revolutionized care. Before that, dissection of all regional lymph nodes was the norm for most patients. After that, the standard of care became a sentinel node biopsy and then—only if the...
SIDEBAR: First Report of Antibody-Drug Conjugate in Advanced Ovarian Cancer
In a related presentation at the AACR Annual Meeting,1 the antibody-drug conjugate DMUC5754A showed encouraging activity in women with ovarian cancer, particularly those with platinum-resistant disease, which currently lacks effective treatment options. The first-in-human phase I study included 44...
Higher HER2 Expression Linked to Best Results with T-DM1 in Patients with HER2-positive Metastatic Breast Cancer
A biomarker analysis of the pivotal EMILIA trial suggests that women with metastatic HER2-positive breast cancer with tumors that have high expression of HER2 derive the most robust benefit from treatment with the antibody-drug conjugate T-DM1 (also now known as ado-trastuzumab emtansine...
Emil 'Tom' Frei III, MD, Trailblazer in the Development of Combination Chemotherapy, Dies at 89
The pages of medical history are dog-eared with breakthroughs that have transformed medicine and saved lives. One of those dog-eared pages belongs to Emil Frei III, MD, known to his colleagues and friends as Tom. In the dawn of oncology, Dr. Frei, along with his associate, Emil Freireich, MD, did...
Saul N. Weingart, MD, PhD, Named New Chief Medical Officer of Tufts Medical Center
Tufts Medical Center has appointed Saul N. Weingart, MD, PhD, of Newton, Massachusetts as its next Chief Medical Officer. Dr. Weingart is currently serving as Vice President for Quality Improvement and Patient Safety at Dana-Farber Cancer Institute in Boston. He is a nationally renowned leader in...
High Levels of Psychological Distress Are Common among Parents of Children with Advanced Cancer
High to severe levels of psychological distress are common among parents of children with advanced cancer, according to a study conducted at three children’s hospitals—Boston Children’s Hospital, Children’s Hospital of Philadelphia, and Seattle Children’s Hospital. The cohort study was embedded in...
Ruxolitinib Results in Clinically Meaningful Symptom Improvement
Patients with myelofibrosis who received ruxolitinib (Jakafi) therapy experienced “meaningful reductions in symptom burden” and improvements in quality of life in a double-blind, placebo-controlled phase III trial published in the Journal of Clinical Oncology. The COMFORT-I (Controlled...
Cisplatin and Radiotherapy Linked to Increased Renal Cancer Risk in Childhood Cancer Survivors
Survivors of childhood cancer have an increased risk of subsequent renal cancers compared to the general population, researchers reported in the Journal of the National Cancer Institute. The risk is particularly high among survivors of neuroblastoma and those who have had irradiation involving the...
High-dose Liposomal Vincristine Produces Durable Responses in Advanced ALL
High-dose monotherapy with vincristine sulfate liposome injection (Marqibo) resulted in meaningful clinical outcomes, including durable responses and bridging to hematopoietic cell transplantation, in adult patients with advanced, relapsed, and refractory Philadelphia chromosome (Ph)-negative acute ...
Higher Prediagnosis Body Mass Index Raises Mortality Risk in Endometrial Cancer
Higher prediagnosis body mass index (BMI) increases risk of overall and disease-specific mortality among women diagnosed with endometrial cancer, suggested a study published in the Journal of the National Cancer Institute. Physical activity was associated with reduced risk of all-cause, but not...
Exemestane an Adjuvant Option for Postmenopausal Hormone Receptor–positive Breast Cancer
A phase III open-label trial of exemestane vs anastrozole in postmenopausal women with hormone-dependent early breast cancer found that both agents produced similar median rates of event-free survival—91% for exemestane and 91.2% for anastrozole—as well as similar distant disease-free and...
SIDEBAR: Going Public with Ovarian Cancer Outcomes
Commenting on the study finding that most women with ovarian cancer are not being treated with the recommended standard of care, a New York Times editorial noted, “One of the surest ways to improve performance would be to analyze and make public how well individual doctors and hospitals do in...
Expect Questions about Experience and Outcomes
“Patients are becoming more sophisticated in their ability and willingness to interrogate the health-care system about their care,” according to Robert E. Bristow, MD, MBA, lead author of the study finding that many women with ovarian cancer are not receiving care consistent with National...
Most Women with Ovarian Cancer Do Not Get Guideline-specified Treatment Linked to Survival Benefits
Most women with ovarian cancer are not receiving adequate treatment, as specified in National Comprehensive Cancer Network (NCCN) Guidelines,1 and as a result are being deprived of the survival benefits correlated with guideline-recommended treatment, according to a study presented at the Society...
Obese Men with Benign Biopsy at High Risk for Prostate Cancer
Obese men were more likely to have precancerous lesions detected in their benign prostate biopsies compared with nonobese men and were at a greater risk for subsequently developing prostate cancer, according to data published recently in Cancer Epidemiology, Biomarkers & Prevention.1 “Our study ...
Symptom Management with Complementary Therapies for Patients Receiving Radiation Therapy
The supportive care of patients with cancer receiving radiotherapy is an important responsibility for the radiation oncologist, and complementary therapies are an integral component of many patients’ treatment strategy.A recent prospective study suggests that 54% of patients with breast cancer...
Society of Interventional Radiology 2013–2014 Officers and Executive Council Members Assume New Roles
Scott C. Goodwin, MD, FSIR, an interventional radiologist and Hasso Brothers Professor and Chair of the Department of Radiological Sciences at the University of California, Irvine, assumed office as the 2013–2014 President of the Society of Interventional Radiology (SIR) during the Society’s 38th...
Common Deletion in APOBEC3 Genes Associated with Increased Risk of Breast Cancer
Genome-wide association studies have identified numerous genetic susceptibility loci for breast cancer, although these loci explain only a small proportion of heritability. Relatively few studies have assessed associations of breast cancer risk with copy number variation, another important source...
HDAC Inhibition Circumvents EGFR Tyrosine Kinase Inhibitor Resistance Due to BIM Polymorphism
Upregulation of BIM (BCL2L11), a proapoptotic member of the BCL2 protein family, is required for induction of apoptosis by EGFR tyrosine kinase inhibitors in EGFR-mutant forms of non–small cell lung cancer (NSCLC). A BIM deletion polymorphism occurs naturally in approximately 13% of East Asian...
Epithelial-to-mesenchymal Transition and Autophagy Induction in Breast Carcinoma Promote Escape from T-cell–mediated Lysis
Epithelial-to-mesenchymal transition is known to mediate cancer cell invasion, metastasis, and drug resistance, but its impact on cancer immune surveillance is less well defined. In a study reported in Cancer Research, Akalay and colleagues found that epithelial-to-mesenchymal transition and...
C-Reactive Protein Downregulates TRAIL, a Cytokine with Key Role in Cancer Immune Surveillance
C-reactive protein is a biomarker of acute and chronic inflammation that is frequently elevated in patients with cancer. In a study reported in Clinical Cancer Research, Secchiero and colleagues found that increased levels of C-reactive protein were associated with downregulation of TRAIL, a...
Control of Autophagic Cell Death by Caspase-10 in Multiple Myeloma
Multiple myeloma subtypes are driven by a variety of genetic abnormalities. Given the genetic diversity of the disease, identification of oncogenic mechanisms common to all subtypes is highly desirable. In a study reported in Cancer Cell, Lamy and colleagues found that that all multiple myeloma...
Mammography Screening and DCIS
I would like to suggest that ASCO take a proactive approach to the treatment of ductal carcinoma in situ (DCIS) and the problem it presents to the oncology community. There has been and continues to be heated debate around the value of mammography screening because of “overdiagnosis,” which in my...
FDA Warns about Potential Medication Errors
The FDA recently alerted health-care professionals that the use of the incorrect nonproprietary name for the breast cancer drug Kadcyla (ado-trastuzumab emtansine, also known as T-DM1 during preapproval clinical trials) in some medication-related electronic systems poses a risk of mix-up with...
Seasons: A Series of Haiku
sunrise the winter tree not so bare I forget to take my pain medication … first robin long summer hikes my vitamin D level still low ignoring my no another leaf falls … About the Author Jyothirmai Gubili is an editor with the Integrative Medicine Service at Memorial Sloan-Kettering Cancer...
The ASCO Post Up Close: Our Reporters and Contributors
About the Writers Charlotte Bath has been writing about cancer and related fields of medicine since serving as Public Information Director of the American Cancer Society, Long Island Division, from 1975 to 1979. She subsequently worked as a writer for Memorial Sloan-Kettering Cancer Center and...
George Salti, MD, Appointed as Co–Medical Director of Edward Cancer Center, Naperville, Illinois
George Salti, MD, FACS, Surgical Oncologist and Associate Professor of Surgery at the University of Illinois at Chicago, has joined the Edward Cancer Center in Naperville, Illinois. Dr. Salti will serve as the Co-Medical Director of the Edward Cancer Center and Medical Director of the Edward...
Living with the Fear of Cancer
After a friend was diagnosed with breast cancer, I became so worried it would happen to me, I decided to perform regular breast self-exams so I could familiarize myself with the normal feel of my breasts, and quickly spot any changes. My friend’s diagnosis scared me, and that fear probably saved my ...
Dr. Bernard Fisher's Breast Cancer Research Left a Lasting Legacy of Improved Therapeutic Efficacy and Survival
Bernard Fisher, MD, is recognized today for his groundbreaking research in breast cancer, which ultimately ended the standard practice of performing the Halsted radical mastectomy, a treatment that had been in place for more than 75 years. His laboratory and clinical investigations led to more...
Robert S. Miller, MD, FACP, Appointed Editor-in-Chief of ASCO's Patient Information Website, Cancer.Net
Robert S. Miller, MD, FACP, has been appointed Editor-in-Chief of ASCO’s patient information website, Cancer.Net. Dr. Miller will assume this role at the 2013 ASCO Annual Meeting in Chicago on June 1, and succeeds Diane Blum, MSW, Chief Executive Officer for the Lymphoma Research Foundation, who...
Drug Approvals in Acute Myeloid Leukemia: Can We Do Better?
Forty years ago, President Richard Nixon announced a “war on cancer.” Some of that war’s first battles were won in the field of acute myeloid leukemia (AML) with two agents, cytarabine and daunorubicin, receiving U.S. Food and Drug Administration (FDA) approval based on their ability to produce...
Focus on Alaska's Denali Oncology Group
Located in Anchorage, Alaska, the Denali Oncology Group faces the dual challenge of serving a diverse and large population of more than 731,000 spread across a vast state of 586,000 square miles, with just 20 medical oncologists and 5 radiation oncologists located mainly in Alaska’s two biggest...
Memorial Sloan-Kettering Cancer Center Announces New Appointments
Memorial Sloan-Kettering Cancer Center in New York recently announced the following appointments: Chief of Lymphoma Anas Younes, MD, has been named Chief of the Lymphoma Service in the Division of Hematologic Oncology, Department of Medicine. An internationally recognized medical oncologist with...
